MCID: SZR006
MIFTS: 56

Seizure Disorder

Categories: Rare diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Seizure Disorder

MalaCards integrated aliases for Seizure Disorder:

Name: Seizure Disorder 54 6 3
Seizures 29 6 43
Seizure Disorders 29 6
Epilepsy 73
Seizure 29

Classifications:



Summaries for Seizure Disorder

NINDS : 54 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Seizure Disorder, also known as seizures, is related to epileptic encephalopathy, early infantile, 6 and alacrima, achalasia, and mental retardation syndrome, and has symptoms including back pain, headache and pain. An important gene associated with Seizure Disorder is SCN1A (Sodium Voltage-Gated Channel Alpha Subunit 1), and among its related pathways/superpathways is Neuroscience. The drugs Vigabatrin and Diazepam have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and temporal lobe, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

MedlinePlus : 43 Seizures are symptoms of a brain problem. They happen because of sudden, abnormal electrical activity in the brain. When people think of seizures, they often think of convulsions in which a person's body shakes rapidly and uncontrollably. Not all seizures cause convulsions. There are many types of seizures and some have mild symptoms. Seizures fall into two main groups. Focal seizures, also called partial seizures, happen in just one part of the brain. Generalized seizures are a result of abnormal activity on both sides of the brain. Most seizures last from 30 seconds to 2 minutes and do not cause lasting harm. However, it is a medical emergency if seizures last longer than 5 minutes or if a person has many seizures and does not wake up between them. Seizures can have many causes, including medicines, high fevers, head injuries and certain diseases. People who have recurring seizures due to a brain disorder have epilepsy. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 What’s New

Wikipedia : 76 Epilepsy is a group of neurological disorders characterized by epileptic seizures. Epileptic seizures... more...

Related Diseases for Seizure Disorder

Diseases in the Seizure Disorder family:

Seizures, Benign Familial Infantile, 1 Seizures, Benign Familial Infantile, 2
Seizures, Benign Familial Infantile, 3 Seizures, Benign Familial Infantile, 4
Seizures, Benign Familial Infantile, 5 Scn1a-Related Seizure Disorders

Diseases related to Seizure Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 epileptic encephalopathy, early infantile, 6 32.0 CDKL5 KCNQ2 PNPO SCN1A
2 alacrima, achalasia, and mental retardation syndrome 30.6 DYRK1A GNB1 MECP2 OTUD6B PURA
3 encephalopathy 30.5 CDKL5 FRRS1L MECP2 PNPO SCN1A
4 microcephaly 30.2 CDKL5 DYRK1A MECP2 POGZ UBE3A
5 autism 30.1 CDKL5 GSPT2 MECP2 POGZ UBE3A
6 scn1a-related seizure disorders 12.1
7 kifafa seizure disorder 12.1
8 infancy electroclinical syndrome 11.0 CDKL5 KCNQ2 SCN1A
9 neonatal period electroclinical syndrome 11.0 CDKL5 KCNQ2 SCN1A
10 epileptic encephalopathy, early infantile, 9 11.0 CDKL5 KCNQ2 MECP2 SCN1A
11 isolated brachycephaly 10.9 FGFR3 POGZ
12 epileptic encephalopathy, early infantile, 15 10.9 CDKL5 KCNQ2 PNPO SCN1A
13 bruxism 10.9 CDKL5 FRRS1L MECP2
14 infantile hypotonia 10.9 MECP2 NALCN
15 west syndrome 10.9 CDKL5 KCNQ2 MECP2 SCN1A WDR45
16 gait apraxia 10.8 CDKL5 MECP2
17 early myoclonic encephalopathy 10.8
18 pervasive developmental disorder 10.8 CDKL5 MECP2 UBE3A
19 wolf-hirschhorn syndrome 10.8
20 strabismus 10.7 FGFR3 GNB1 NALCN POGZ
21 hypotonia 10.7 GNB1 MECP2 NALCN PURA UBE3A
22 angelman syndrome 10.6 CDKL5 MECP2 UBE3A
23 benign childhood occipital epilepsy, panayiotopoulos type 10.6
24 epileptic encephalopathy, early infantile, 7 10.6
25 epileptic encephalopathy, early infantile, 11 10.6
26 epilepsy, idiopathic generalized 10.6 CDKL5 KCNQ2 SCN1A
27 seizures, benign familial infantile, 3 10.4 KCNQ2 SCN1A
28 aicardi syndrome 10.4
29 genetic epilepsy with febrile seizures plus 10.4
30 epileptic encephalopathy, early infantile, 1 10.4
31 leukodystrophy, hypomyelinating, 12 10.4
32 epileptic encephalopathy, early infantile, 52 10.4
33 seizures, benign familial infantile, 1 10.4
34 epilepsy, juvenile myoclonic 10 10.4
35 generalized epilepsy with febrile seizures plus, type 1 10.4
36 epilepsy, familial focal, with variable foci 4 10.4
37 generalized epilepsy with febrile seizures plus, type 2 10.4
38 cerebral palsy 10.4
39 pyridoxamine 5-prime-phosphate oxidase deficiency 10.4
40 generalized epilepsy with febrile seizures plus, type 3 10.4
41 aicardi-goutieres syndrome 1 10.4
42 nervous system disease 10.4
43 epilepsy, focal, with speech disorder and with or without mental retardation 10.4
44 generalized epilepsy with febrile seizures plus, type 7 10.4
45 febrile seizures, familial, 11 10.4
46 mental retardation, x-linked 12 10.4
47 epilepsy 10.0
48 trehalase deficiency 9.9 CDKL5 DYRK1A FGFR3 GNB1 KCNQ2 MECP2
49 insulinoma 9.9
50 aphasia 9.7

Comorbidity relations with Seizure Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Seizure Disorder:



Diseases related to Seizure Disorder

Symptoms & Phenotypes for Seizure Disorder

UMLS symptoms related to Seizure Disorder:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, non-epileptic convulsion, sleeplessness

GenomeRNAi Phenotypes related to Seizure Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 8.92 DYRK1A
2 Decreased substrate adherent cell growth GR00193-A-3 8.92 CDKL5 DYRK1A FGFR3

MGI Mouse Phenotypes related to Seizure Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 CDKL5 DYRK1A FGFR3 FRRS1L GNB1 KCNQ2
2 mortality/aging MP:0010768 9.93 DYRK1A FGFR3 FRRS1L GNB1 KCNQ2 MECP2
3 nervous system MP:0003631 9.73 GNB1 KCNQ2 MECP2 MYO5A NALCN PURA
4 respiratory system MP:0005388 9.17 FGFR3 GNB1 KCNQ2 MECP2 NALCN PURA

Drugs & Therapeutics for Seizure Disorder

Drugs for Seizure Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vigabatrin Approved Phase 4,Phase 3,Phase 2,Not Applicable 68506-86-5, 60643-86-9 5665
2
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 439-14-5 3016
3
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
4
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
5
Clobazam Approved, Illicit Phase 4,Phase 3,Phase 2 22316-47-8 2789
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
7
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
8
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-41-0 1775
9
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-46-4 2554
10
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
11
Zonisamide Approved, Investigational Phase 4,Phase 3 68291-97-4 5734
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
13
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
14
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
15
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
16
Tranexamic Acid Approved Phase 4,Phase 3 1197-18-8 5526
17
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
18 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7491-74-9
19
Nitrazepam Approved Phase 4,Phase 2 146-22-5 4506
20
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
21
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
22
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
23
Tiagabine Approved, Investigational Phase 4,Phase 1 115103-54-3 60648
24
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-06-6 4763
25
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
27
Ethosuximide Approved Phase 4,Phase 3 77-67-8 3291
28
Felbamate Approved Phase 4 25451-15-4 3331
29
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 159351-69-6 6442177
30
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
31
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2 1622-61-3 2802
32
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
33
Oxcarbazepine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28721-07-5 34312
34
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
35
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
36
Lacosamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 860352-01-8, 175481-36-4 219078
37
Biperiden Approved, Investigational Phase 4,Phase 3 514-65-8 2381
38
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
39
Eslicarbazepine acetate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75970-99-9, 236395-14-5 123618
40
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-12-2 119
41
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
42
Sertraline Approved Phase 4,Phase 3,Not Applicable 79617-96-2 68617
43
Labetalol Approved Phase 4 36894-69-6 3869
44
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
45
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
46
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
47
Norepinephrine Approved Phase 4 51-41-2 439260
48
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
49
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 113775-47-6 68602 5311068
50
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 1715)
# Name Status NCT ID Phase Drugs
1 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
2 Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Unknown status NCT02726919 Phase 4 Clobazam
3 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
4 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
5 Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4 Antiepileptic drug (AED)
6 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
7 BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients Unknown status NCT02404168 Phase 4 lamotrigine (brand Lamictal);lamotrigine (generic Teva)
8 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
9 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
10 A Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
11 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
12 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
13 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
14 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
15 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
16 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
17 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
18 Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability Unknown status NCT02078336 Phase 4 Midazolam Mylan;Lorazepam Mylan;Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
19 Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. Unknown status NCT01478035 Phase 4 Phenytoin;placebo
20 Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies Completed NCT00896987 Phase 4 lamotrigine (Lamictal);Carbamazepine (Tegretol)
21 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study) Completed NCT01733394 Phase 4 Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand";lamotrigine
22 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design Completed NCT01713777 Phase 4 Lamotrigine Generic "A";Lamotrigine generic "B"
23 Standardized Educational Plan for Epilepsy Patients With Comorbidities Completed NCT01804322 Phase 4
24 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study Completed NCT02100644 Phase 4 Lamotrigine tablets 25/100 mg
25 Methylphenidate Treatment of Attention Deficits in Epilepsy Completed NCT02178995 Phase 4 Methylphenidate
26 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
27 RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy Completed NCT00564915 Phase 4
28 Levetiracetam for Benign Rolandic Epilepsy Completed NCT00181116 Phase 4 Levetiracetam
29 Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy Completed NCT00216567 Phase 4 topamax
30 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4 levonorgestrel IUS
31 Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Completed NCT00245713 Phase 4 levetiracetam
32 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4 Lacosamide;Placebo
33 Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4 zonisamide
34 Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy Completed NCT00043914 Phase 4 lamotrigine
35 A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Completed NCT01689649 Phase 4 Topiramate
36 Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures Completed NCT00955357 Phase 4 Lacosamide
37 Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D Completed NCT02890823 Phase 4 Cholecalciferol
38 Study of Valproate in Young Patients Suffering From Epilepsy Completed NCT00385411 Phase 4 valproate microgranules
39 S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00630968 Phase 4 Levetiracetam (Keppra)
40 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy Completed NCT01498822 Phase 4 Levetiracetam;Oxcarbazepine
41 Lamotrigine Bioequivalence Completed NCT01995825 Phase 4 lamotrigine
42 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
43 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Completed NCT00160654 Phase 4 Levetiracetam
44 A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy Completed NCT00266604 Phase 4 Topiramate
45 Switchability Study Between Brand and Generic Topiramate Completed NCT02113787 Phase 4
46 Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy Completed NCT00323947 Phase 4 Extended Release Methylphenidate (OROS-Methylphenidate)
47 Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure Completed NCT01235403 Phase 4 Lacosamide
48 A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00631150 Phase 4 Levetiracetam (Keppra)
49 Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy Completed NCT00630357 Phase 4 Levetiracetam (Keppra)
50 Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy Completed NCT00630630 Phase 4 Levetiracetam

Search NIH Clinical Center for Seizure Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Seizure Disorder

Genetic tests related to Seizure Disorder:

# Genetic test Affiliating Genes
1 Seizures 29
2 Seizure 29
3 Seizure Disorders 29

Anatomical Context for Seizure Disorder

MalaCards organs/tissues related to Seizure Disorder:

41
Brain, Testes, Temporal Lobe, Bone, Heart, Thalamus, Skin

Publications for Seizure Disorder

Articles related to Seizure Disorder:

(show top 50) (show all 215)
# Title Authors Year
1
Asynchronous slipped capital femoral epiphysis in a patient with a seizure disorder: case report and review of the literature. ( 28657919 )
2017
2
Epilepsy or a Seizure Disorder? Parental Knowledge and Misconceptions About Terminology. ( 29173305 )
2017
3
Elevated Urinary Glyphosate and Clostridia Metabolites With Altered Dopamine Metabolism in Triplets With Autistic Spectrum Disorder or Suspected Seizure Disorder: A Case Study. ( 28223908 )
2017
4
Long-term Risk of a Seizure Disorder After Eclampsia. ( 29112665 )
2017
5
Application and Evaluation of Independent Component Analysis Methods to Generalized Seizure Disorder Activities Exhibited in the Brain. ( 27837050 )
2017
6
KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects. ( 26740507 )
2016
7
New Onset Seizure Disorder Following Electroconvulsive Therapy. ( 29782784 )
2016
8
A method for deciding about the possible safety of modafinil and armodafinil in patients with seizure disorder. ( 26845275 )
2016
9
Clinical intrafamilial variability in lethal familial neonatal seizure disorder caused by TBC1D24 mutations. ( 27541164 )
2016
10
Partners in Crime: Kidney Transplantation and Seizure Disorder. ( 27788804 )
2016
11
De novo and inherited mutations in the X-linked gene CLCN4 are associated with syndromic intellectual disability and behavior and seizure disorders in males and females. ( 27550844 )
2016
12
Epilepsy or seizure disorder? The effect of cultural and socioeconomic factors on self-reported prevalence. ( 27494358 )
2016
13
Basal transethmoidal encephalocele and malignant hypertension in a parturient with a seizure disorder. A case report. ( 25745752 )
2015
14
Fish consumption in individuals with Down syndrome with seizure disorder: News for prescription. ( 25625531 )
2015
15
The impact of co-morbid seizure disorder on neuropsychological functioning in children and adolescents with FASD. ( 26531612 )
2015
16
Development of mania with carbamazepine for treatment of seizure disorder in a 7-year-old boy. ( 25650677 )
2015
17
A Case Report of Klinefelter Syndrome with Schizophrenia-Like Psychosis and Seizure Disorder. ( 26664093 )
2015
18
Treatment-resistant mania in Dandy-Walker malformation with seizure disorder: A case report. ( 26962361 )
2015
19
Vegetating plaques in a patient with a seizure disorder. ( 26018379 )
2015
20
Childhood insulinoma masquerading as seizure disorder. ( 24698060 )
2014
21
Seizure disorder secondary to remote gunshot wound of the head: a case of sudden unexpected death in epilepsy. ( 24771478 )
2014
22
Psychosis and seizure disorder: challenges in diagnosis and treatment. ( 25234075 )
2014
23
Absent posterior alpha rhythm: An indirect indicator of seizure disorder? ( 24574560 )
2014
24
Clinico-Electroencephalography Pattern and Determinant of 2-year Seizure Control in Patients with Complex Partial Seizure Disorder in Kano, Northwestern Nigeria. ( 24761235 )
2014
25
Unusual 4p16.3 deletions suggest an additional chromosome region for the Wolf-Hirschhorn syndrome-associated seizures disorder. ( 24738919 )
2014
26
Lennox-lombroso lecture, 2013: psychiatric comorbidities through the life of the seizure disorder: a complex relation with a not so complex solution. ( 25678862 )
2014
27
Seizure Disorder in a Patient with a 5.09 Mb 7q11.23-q21.11 Microdeletion Including the MAGI2 Gene. ( 26030165 )
2014
28
Interictal EEG changes in patients with seizure disorder: experience in Bangladesh. ( 23482637 )
2013
29
A 44-year-old patient with a new-onset seizure disorder after vaccination against Japanese encephalitis: a case report. ( 23497732 )
2013
30
Teachers' knowledge and attitudes towards seizure disorder: a comparative study of urban and rural school teachers in Akwa Ibom State, Nigeria. ( 23771463 )
2013
31
Seizure disorder among chronic kidney disease patients in Enugu, South East Nigeria. ( 24283099 )
2013
32
Maternal seizure disorder and risk of adverse pregnancy outcomes. ( 23380264 )
2013
33
Seizure disorder. ( 23923286 )
2013
34
Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure disorder. ( 24370333 )
2013
35
Aberrant sodium channel activity in the complex seizure disorder of Celf4 mutant mice. ( 23090952 )
2013
36
Assessing Systems of Care for US Children with Epilepsy/Seizure Disorder. ( 24228175 )
2013
37
Chromosomal loss of 3q26.3-3q26.32, involving a partial neuroligin 1 deletion, identified by genomic microarray in a child with microcephaly, seizure disorder, and severe intellectual disability. ( 22106001 )
2012
38
Risk and causes of death in children with a seizure disorder. ( 22500675 )
2012
39
A national profile of childhood epilepsy and seizure disorder. ( 22271699 )
2012
40
Anterior shoulder instability associated with coracoid nonunion in patients with a seizure disorder. ( 22488624 )
2012
41
Insulinoma presenting as refractory seizure disorder. ( 24358830 )
2012
42
Risk and causes of death in children with a seizure disorder. ( 22571767 )
2012
43
Dextromethorphan abuse masquerading as a recurrent seizure disorder. ( 21378523 )
2011
44
Afebrile seizures associated with respiratory syncytial virus infection: a situation-related seizure disorder in early infancy. ( 21342339 )
2011
45
First-onset psychotic disorder concurrent with a first-onset seizure disorder. ( 22231334 )
2011
46
Variable expressivity of a novel mutation in the SCN1A gene leading to an autosomal dominant seizure disorder. ( 21775168 )
2011
47
Etiology of a genetically complex seizure disorder in Celf4 mutant mice. ( 21745337 )
2011
48
Successful Gamma Knife-based stereotactic radiosurgery treatment for medically intractable heterotopia-based seizure disorder. ( 21803485 )
2011
49
20p11 deletion in a female child with panhypopituitarism, cleft lip and palate, dysmorphic facial features, global developmental delay and seizure disorder. ( 21204230 )
2011
50
Clobazam approved for seizure disorder. ( 22095800 )
2011

Variations for Seizure Disorder

ClinVar genetic disease variations for Seizure Disorder:

6
(show top 50) (show all 626)
# Gene Variation Type Significance SNP ID Assembly Location
1 SCO2 NM_005138.2(SCO2): c.418G> A (p.Glu140Lys) single nucleotide variant Pathogenic rs74315511 GRCh37 Chromosome 22, 50962423: 50962423
2 SCO2 NM_005138.2(SCO2): c.418G> A (p.Glu140Lys) single nucleotide variant Pathogenic rs74315511 GRCh38 Chromosome 22, 50523994: 50523994
3 TSHR NM_000369.2(TSHR): c.122G> C (p.Cys41Ser) single nucleotide variant Pathogenic rs121908869 GRCh37 Chromosome 14, 81422146: 81422146
4 TSHR NM_000369.2(TSHR): c.122G> C (p.Cys41Ser) single nucleotide variant Pathogenic